Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Sunvozertinib shows promise for NSCLC with EGFR exon 20 insertion mutations, achieving a 53.3% ORR in the WU-KONG1 trial. The FDA application is supported by phase 2 trial data, with a focus on ...

Around 13% of DMD patients respond to exon 51 skipping, but PepGen reckons other drugs in its pipeline will address mutations that are central to around 35% of all cases of the disease.

Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling. Elevidys ...

PROGRESSIVE muscular dystrophy was recognized over a century ago, and Gowers noted its familial occurrence soon afterward. The disease, which is similar in affected members of a family, may vary ...

We identified a novel and significant association between Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder. The eight cases with both diagnoses presented ...

Chicago's eastern boundary is formed by Lake Michigan, and the city is divided by the Chicago River into three geographic sections: the North Side, the South Side and the West Side. These sections ...